Evidence map›Paper›PMID 38030604›Full record

ArticleCell death & disease2023

Phosphorylation of USP27X by GSK3β maintains the stability and oncogenic functions of CBX2.

Yushu Xing, Jirimu Ba-Tu, Chongyang Dong, Xiaodong Cao, Bing Li, Xin Jia, Yu Juan, Xiaojie Lv, Huiwen Zhang, Na Qin and 9 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Yushu XingCollege of Pharmacy, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Jirimu Ba-TuMedical Innovation Center for Nationalities, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Chongyang DongCollege of Traditional Chinese Medicine, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Xiaodong CaoCollege of Pharmacy, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Bing LiCollege of Pharmacy, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Xin JiaCollege of Pharmacy, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Yu JuanCollege of Pharmacy, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Xiaojie LvCollege of Pharmacy, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Huiwen ZhangCollege of Pharmacy, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Na QinCollege of Mongolian Medicine, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Wuri HanCollege of Mongolian Medicine, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Dongfeng WangCollege of Traditional Chinese Medicine, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Xiao QiCollege of Pharmacy, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Yutong WangCollege of Pharmacy, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Xulu HaoCollege of Traditional Chinese Medicine, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Shuang ZhangCollege of Traditional Chinese Medicine, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China.
Xiaoli DuCollege of Pharmacy, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China. 48121567@qq.com.ORCID 0000-0003-0293-116X
Huanyun WangCollege of Pharmacy, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China. whuanyun999@163.com.ORCID 0000-0002-6105-338X
Minjie WangMedical Experimental Center of Basic Medical School, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China. wangminjienmg@163.com.ORCID 0000-0002-7698-4312
Inner Mongolia Medical University · CN

Funding

Natural Science Foundation of Inner Mongolia (Inner Mongolian Natural Science Foundation) 2022MS08023Natural Science Foundation of Inner Mongolia (Inner Mongolian Natural Science Foundation) No. 2022MS08025
6 · The paper itself

Abstract

Chromobox protein homolog 2 (CBX2) exerts a multifaceted impact on the progression of aggressive cancers. The proteasome-dependent pathway is crucial for modulating CBX2 regulation, while the specific regulatory roles and mechanisms of deubiquitinating enzymes targeting CBX2 remain poorly understood. Mass spectrometry analysis identified ubiquitin-specific peptidase 27X (USP27X) as a deubiquitinating enzyme that targets CBX2. Overexpression of USP27X significantly enhances CBX2 levels by promoting deubiquitination, while deficiency of USP27X leads to CBX2 degradation, thereby inhibiting tumorigenesis. Furthermore, it has been revealed that glycogen synthase kinase 3 beta (GSK3β) can directly bind to and phosphorylate USP27X, thereby enhancing the interaction between USP27X and CBX2 and leading to further stabilization of the CBX2 protein. Clinically, the co-expression of high levels of USP27X and CBX2 in breast cancer tissues is indicative of a poor prognosis for patients with this disease. These findings collectively underscore the critical regulatory role played by USP27X in modulating CBX2, thereby establishing the GSK3β-USP27X-CBX2 axis as a pivotal driver of malignant progression in breast cancer.

Indexed as

Breast NeoplasmsUbiquitin-Specific ProteasesFemaleGlycogen Synthase Kinase 3 betaHumansPhosphorylationPolycomb Repressive Complex 1Transcription FactorsCBX2 protein, humanGlycogen Synthase Kinase 3 betaGSK3B protein, humanPolycomb Repressive Complex 1Transcription FactorsUbiquitin-Specific ProteasesUSP27X protein, human

Identifiers

PMID38030604
PMCPMC10687032
OpenAlexW4389147086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.